+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Statin-associated myasthenic weakness

Statin-associated myasthenic weakness

Journal of the Medical Association of Thailand 94(2): 256-258

Statin-associated myasthenic weakness is uncommonly recognized. Since 2002, there have been 14 cases described in literatures. However, the underlying mechanism is still unknown. In 2007, a 50-year-old woman with generalized, limb predominated, myasthenia gravis (MG), whose MG status has been "minimal manifestation" for several years, developed moderately severe fluctuating bulbar weakness a few weeks after starting simvastatin 20 mg/day. Simvastatin was discontinued and dosage of cholinesterase inhibitor was temporarily increased. The symptoms resolved and she was back to her previous status in one month. In 2008, two weeks after re-challenge with simvastatin 10 mg/day, bulbar weakness re-occurred Antibody to acetylcholine receptors was measured 4.25 nmole/L. Serum creatine phosphokinase was normal. Electrophysiologic tests showed evidences of postsynaptic neuromuscular junction disorder without evidence of myopathy. The symptoms were again resolved after discontinuation of statin and temporarily increased dosage of cholinesterase inhibitor. She was back to previous status in two months. Hypercholesterolemia was then controlled with ezetimibe without any worsening in MG status. Because of the wide use of statins in clinical practice, physicians should be aware of this potential adverse effect. The incidence ofstatin-associated myasthenic weakness should be clearly investigated Challenge with other brands of statin or with reduced dosage is not beneficial in these patients. Non-pharmacological treatment and non-statin medication may be considered

(PDF emailed within 1 workday: $29.90)

Accession: 055911544

Download citation: RISBibTeXText

PMID: 21534375

Related references

Predicting the course of myasthenic weakness following double filtration plasmapheresis. Acta Neurologica Scandinavica 108(3): 174-178, September, 2003

Isolated proximal muscular weakness disclosing myasthenic syndrome. Revue Neurologique 150(5): 377-381, 1994

Respiratory muscle weakness in the Lambert-Eaton myasthenic syndrome. Thorax 44(11): 913-918, 1989

Congenital Myasthenic Syndromes with Predominant Limb Girdle Weakness. Journal of Neuromuscular Diseases 2(Suppl 2): S21-S29, 2016

Lambert-Eaton myasthenic syndrome with pure ocular weakness. Neurology 68(21): 1863-1864, 2007

Re: Lambert-Eaton myasthenic syndrome with pure ocular weakness. Neurology 70(1): 86; Author Reply 86-7, 2008

On the double: Early immunotherapy speeds recovery of ocular myasthenic weakness. Muscle & Nerve, 2018

Correlation between regional myasthenic weakness and mental aspects of quality of life. European Journal of Neurology 13(2): 191-193, 2006

Patients with CACNA1A mutations and associated myasthenic weakness have presynaptic failure of neuromuscular transmission. Neurology 56(8 Supplement 3): A60, April 24, 2001

Pure Ocular Weakness as the Initial Manifestation of Lambert-Eaton Myasthenic Syndrome. Cureus 9(12): E2007-E2007, 2018

Spontaneous thymoma rat as a model for myasthenic weakness caused by anti-ryanodine receptor antibodies. Muscle & Nerve 21(12): 1655-1660, 1998

Studies in myasthenia gravis: use of edrophonium chloride (Tensilon) in differentiating myasthenic from cholinergic weakness. A.M.A. Archives of Neurology and Psychiatry 70(3): 385-392, 1953

Difference in distribution of muscle weakness between myasthenia gravis and the Lambert-Eaton myasthenic syndrome. Journal of Neurology, Neurosurgery, and Psychiatry 73(6): 766-768, 2002

Agrin mutations lead to a congenital myasthenic syndrome with distal muscle weakness and atrophy. Brain 137(Pt 9): 2429-2443, 2014

Persisting weakness after withdrawal of a statin. Bmj Case Reports 2014: -, 2014